NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 7, 2010, Pages 871-890

  Pavletic, Steven Z ^a   Kumar, Shaji ^b   Mohty, Mohamad ^c   de Lima, Marcos ^d   Foran, James M ^e   Pasquini, Marcelo ^f   Zhang, Mei Jie ^f   Giralt, Sergio ^d   Bishop, Michael R ^a   Weisdorf, Daniel ^g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Allogeneic hematorpoietic stem cell transplantation; Relapse

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BORTEZOMIB; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; FLUDARABINE; IMATINIB; IMMUNOMODULATING AGENT; INTERFERON; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMORBIDITY; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EPIDEMIOLOGY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HODGKIN DISEASE; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATIENT MONITORING; PROBABILITY; REDUCED INTENSITY CONDITIONING; REVIEW; RISK FACTOR; TREATMENT FAILURE; UNIVARIATE ANALYSIS;

GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 77953587073     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.04.004     Document Type: Review

References (244)

1. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
2. Ringden O., Pavletic S.Z., Anasetti C., et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009, 113:3110-3118.
3. Dreger P., Brand R., Hansz J., et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003, 17:841-848.
4. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002, 100:406-414.
5. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304:1529-1533.
6. Sullivan K.M., Weiden P.L., Storb R., et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989, 73:1720-1728.
7. Ringden O., Labopin M., Gluckman E., et al. Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Transplant Proc 1997, 29:733-734.
8. Gratwohl A., Brand R., Apperley J., et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002, 100:3877-3886.
9. Ozawa S., Nakaseko C., Nishimura M., et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol 2007, 137:142-151.
10. Lee S., Cho B.S., Kim S.Y., et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:1083-1094.
11. Toze C.L., Galal A., Barnett M.J., et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 2005, 36:825-830.
12. Bierman P.J., Sweetenham J.W., Loberiza F.R., et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003, 21:3744-3753.
13. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005, 23:1993-2003.
14. Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008, 26:577-584.
15. Sureda A., Robinson S., Canals C., et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008, 26:455-462.
16. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
17. Arora M., Weisdorf D.J., Spellman S.R., et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009, 27:1644-1652.
18. Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113:726-732.
19. Brunstein C.G., Wagner J.E., Weisdorf D.J., et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009, 113:5628-5634.
20. Miller J.S., Cooley S., Parham P., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007, 109:5058-5061.
21. Narimatsu H., Miyakoshi S., Yamaguchi T., et al. Chronic graft-versus-host disease following umbilical cord blood transplantation: retrospective survey involving 1072 patients in Japan. Blood 2008, 112:2579-2582.
22. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276-2285.
23. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft versus leukemia effect in recipients of two units. Blood 2009.
24. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
25. Storb R., Deeg H.J., Fisher L., et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988, 71:293-298.
26. Storb R., Deeg H.J., Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989, 73:1729-1734.
27. Aschan J., Ringden O., Sundberg B., Gahrton G., Ljungman P., Winiarski J. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991, 7:113-119.
28. Weaver C.H., Clift R.A., Deeg H.J., et al. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 1994, 14:885-893.
29. Bacigalupo A., Van Lint M.T., Occhini D., et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991, 77:1423-1428.
30. Aschan J., Ringden O., Sundberg B., Klaesson S., Ljungman P., Lonnqvist B. Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. Eur J Haematol 1993, 50:269-274.
31. Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
32. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130.
33. Wagner J.E., Thompson J.S., Carter S.L., Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741.
34. Pavletic S.Z., Carter S.L., Kernan N.A., et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005, 106:3308-3313.
35. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
36. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
37. Kroger N., Zabelina T., Kruger W., et al. Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 2001, 80:209-215.
38. Remberger M., Storer B., Ringden O., Anasetti C. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002, 29:391-397.
39. Remberger M., Svahn B.M., Mattsson J., Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004, 78:122-127.
40. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
41. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005, 23:9387-9393.
42. Huff C.A., Fuchs E.J., Noga S.J., et al. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant 2003, 9:312-319.
43. Alyea E., Weller E., Schlossman R., et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001, 98:934-939.
44. Finke J., Schmoor C., Lang H., Potthoff K., Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 2003, 21:506-513.
45. Hale G., Zhang M.-J., Bunjes D., et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998, 92:4581-4590.
46. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
47. Ho V.T., Aldridge J., Kim H.T., et al. Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:844-850.
48. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
49. Neumann F., Graef T., Tapprich C., et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine a and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005, 35:1089-1093.
50. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003, 101:1620-1629.
51. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after hla-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
52. Chao N.J., Snyder D.S., Jain M., et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 2000, 6:254-261.
53. Baan C.C., van der Mast B.J., Klepper M., et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005, 80:110-117.
54. Carlens S., Aschan J., Remberger M., Dilber M., Ringden O. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. Bone Marrow Transplant 1999, 24:629-635.
55. Koca E., Champlin R.E. Peripheral blood progenitor cell or bone marrow transplantation: controversy remains. Curr Opin Oncol 2008, 20:220-226.
56. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
57. Ringden O., Remberger M., Runde V., et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999, 94:455-464.
58. Sorror M.L., Storer B.E., Maloney D.G., Sandmaier B.M., Martin P.J., Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008, 111:446-452.
59. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
60. Fung H.C., Stein A., Slovak M., et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003, 9:766-771.
61. Falini B., Nicoletti I., Martelli M.F., Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109:874-885.
62. Gale R.E., Green C., Allen C., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111:2776-2784.
63. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
64. Gale R.E., Hills R., Pizzey A.R., et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 2005, 106:3768-3776.
65. Bornhauser M., Illmer T., Schaich M., Soucek S., Ehninger G., Thiede C. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 2007, 109:2264-2265. author reply 2265.
66. Swirsky D.M., de Bastos M., Parish S.E., Rees J.K., Hayhoe F.G. Features affecting outcome during remission induction of acute myeloid leukaemia in 619 adult patients. Br J Haematol 1986, 64:435-453.
67. Burnett A.K., Grimwade D., Solomon E., Wheatley K., Goldstone A.H. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC Trial. Blood 1999, 93:4131-4143.
68. Chang C., Storer B.E., Scott B.L., et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007, 110:1379-1387.
69. Leith C.P., Kopecky K.J., Chen I.M., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999, 94:1086-1099.
70. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010.
71. Serna D.S., Lee S.J., Zhang M.J., et al. Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada. J Clin Oncol 2003, 21:3754-3760.
72. Baker K.S., Loberiza F.R., Yu H., et al. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol 2005, 23:7032-7042.
73. Schwake C.J., Eapen M., Lee S.J., et al. Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities. Biol Blood Marrow Transplant 2005, 11:988-998.
74. Sierra J., Storer B., Hansen J.A., et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000, 26:397-404.
75. Bacigalupo A., Sormani M.P., Lamparelli T., et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 2004, 89:1238-1247.
76. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
77. Majhail N.S., Brunstein C.G., Wagner J.E. Double umbilical cord blood transplantation. Curr Opin Immunol 2006, 18:571-575.
78. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Blood 2007, 110:3064-3070.
79. Randolph S.S., Gooley T.A., Warren E.H., Appelbaum F.R., Riddell S.R. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004, 103:347-352.
80. Blaise D., Vey N., Faucher C., Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2007, 92:533-541.
81. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006, 24:444-453.
82. Blaise D.P., Michel Boiron J., Faucher C., et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005, 104:1931-1938.
83. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865-872.
84. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
85. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006, 20:322-328.
86. Oran B., Giralt S., Couriel D., et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007, 21:2540-2544.
87. Kroger N., Brand R., van Biezen A., et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009, 94:542-549.
88. Nakamura R., Rodriguez R., Palmer J., et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant 2007, 40:843-850.
89. Oliansky D.M., Antin J.H., Bennett J.M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 2009, 15:137-172.
90. De Padua Silva L., de Lima M., Kantarjian H., et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009, 42:839-843.
91. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
92. Field T., Perkins J., Huang Y., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45:255-260.
93. Litzow M.R., Tarima S., Perez W.S., et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010, 115:1850-1857.
94. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
95. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004, 104:1616-1623.
96. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
97. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006, 20:128-135.
98. Spellman S., Warden M.B., Haagenson M., et al. Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. Biol Blood Marrow Transplant 2009, 15:856-863.
99. Gutman J.A., Leisenring W., Appelbaum F.R., Woolfrey A.E., Delaney C. Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. Biol Blood Marrow Transplant 2009, 15:1122-1129.
100. Brunstein C.G., Gutman J.A., DeFor T.E., et al. Reduced relapse and similar progression-free survival after double umbilical cord blood transplantation (DUCBT): comparison of outcomes between sibling, unrelated adult and unrelated DUCB hematopoietic stem cell (HSC) donors. ASH Ann Meet Abstr 2009, 114:662.
101. Castro-Malaspina H., Jabubowski A.A., Papadopoulos E.B., et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 2008, 14:458-468.
102. Mattsson J., Uzunel M., Tammik L., Aschan J., Ringden O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001, 15:1976-1985.
103. Eapen M., Giralt S.A., Horowitz M.M., et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004, 34:721-727.
104. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
105. Goldman J., Sobocinski K., Zang A., Klein J.P. Long-term outcome after allogeneic hematopoietic (HCT) for CML. Biol Blood Marrow Transplant 2007, 12:17.
106. Goldman J.M., Apperley J.F., Jones L., et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986, 314:202-207.
107. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91:513-521.
108. Passweg J.R., Walker I., Sobocinski K.A., et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004, 125:613-620.
109. Jabbour E., Cortes J., Kantarjian H.M., et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006, 108:1421-1423.
110. Jabbour E., Cortes J., Kantarjian H., et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 2007, 110:340-344.
111. Oehler V.G., Gooley T., Snyder D.S., et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007, 109:1782-1789.
112. Crawley C., Szydlo R., Lalancette M., et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005, 106:2969-2976.
113. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
114. Kebriaei P., Detry M.A., Giralt S., et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007, 110:3456-3462.
115. Giralt S., Hester J., Huh Y., et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995, 86:4337-4343.
116. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002, 100:1590-1595.
117. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268.
118. Hahn T., Wall D., Camitta B., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2006, 12:1-30.
119. Fielding A.K., Richards S.M., Chopra R., et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007, 109:944-950.
120. Bachanova V., Weisdorf D. Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review. Bone Marrow Transplant 2008, 41:455-464.
121. Cornelissen J.J., Carston M., Kollman C., et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001, 97:1572-1577.
122. Thiebaut A., Vernant J.P., Degos L., et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000, 14:1353-1366. x.
123. Labar B., Suciu S., Zittoun R., et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients < or =50 years old in first complete remission: results of the EORTC ALL-3 trial. Haematologica 2004, 89:809-817.
124. Ringden O., Labopin M., Bacigalupo A., et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002, 20:4655-4664.
125. Ribera J.M., Oriol A., Bethencourt C., et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005, 90:1346-1356.
126. Hunault M., Harousseau J.L., Delain M., et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004, 104:3028-3037.
127. Gupta V., Yi Q.L., Brandwein J., et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant 2004, 33:397-404.
128. Yanada M., Matsuo K., Suzuki T., Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006, 106:2657-2663.
129. Moorman A.V., Harrison C.J., Buck G.A., et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007, 109:3189-3197.
130. Tomblyn M.B., Arora M., Baker K.S., et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol 2009, 27:3634-3641.
131. Weisdorf D., Bishop M., Dharan B., et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant 2002, 8:213-220.
132. Bishop M.R., Logan B.R., Gandham S., et al. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant 2008, 41:635-642.
133. Arnold R., Massenkeil G., Bornhauser M., et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002, 16:2423-2428.
134. Martino R., Giralt S., Caballero M.D., et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica 2003, 88:555-560.
135. Massenkeil G., Nagy M., Neuburger S., et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant 2005, 36:683-689.
136. Hamaki T., Kami M., Kanda Y., et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transplant 2005, 35:549-556.
137. Barlogie B., Anaissie E., van Rhee F., et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007, 138:176-185.
138. Mohty M., Labopin M., Tabrizzi R., et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008, 93:303-306.
139. Bachanova V., Verneris M.R., DeFor T., Brunstein C.G., Weisdorf D.J. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009, 113:2902-2905.
140. Sierra J., Radich J., Hansen J.A., et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997, 90:1410-1414.
141. Marks D.I., Perez W.S., He W., et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 2008, 112:426-434.
142. Marks D.I., Bird J.M., Cornish J.M., et al. Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia. J Clin Oncol 1998, 16:931-936.
143. Carpenter P.A., Snyder D.S., Flowers M.E., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791-2793.
144. Talano J.M., Casper J.T., Camitta B.M., et al. Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL. Bone Marrow Transplant 2006, 37:135-141.
145. Laport G.G., Alvarnas J.C., Palmer J.M., et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 2008, 112:903-909.
146. Bunin N., Aplenc R., Kamani N., Shaw K., Cnaan A., Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003, 32:543-548.
147. Hahn T., Wall D., Camitta B., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 2005, 11:823-861.
148. Marks D.I., Forman S.J., Blume K.G., et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 2006, 12:438-453.
149. Garderet L., Labopin M., Gorin N.C., et al. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. Bone Marrow Transplant 2003, 31:23-29.
150. Kiehl M.G., Kraut L., Schwerdtfeger R., et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004, 22:2816-2825.
151. Dahlke J., Kroger N., Zabelina T., et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant 2006, 37:155-163.
152. Gahrton G., Svensson H., Cavo M., et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001, 113:209-216.
153. Bjorkstrand B.B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996, 88:4711-4718.
154. Crawley C., Iacobelli S., Bjorkstrand B., Apperley J.F., Niederwieser D., Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007, 109:3588-3594.
155. Bruno B., Rotta M., Patriarca F., et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009, 113:3375-3382.
156. Rotta M., Storer B.E., Sahebi F., et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009, 113:3383-3391.
157. Alyea E., Weller E., Schlossman R., et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 2003, 32:1145-1151.
158. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005, 105:4532-4539.
159. Schilling G., Hansen T., Shimoni A., et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008, 22:1250-1255.
160. Gahrton G., Bjorkstrand B. Allogeneic transplantation in multiple myeloma. Haematologica 2008, 93:1295-1300.
161. Hunter H.M., Peggs K., Powles R., et al. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning-evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005, 128:496-502.
162. Georges G.E., Maris M.B., Maloney D.G., et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 2007, 13:423-432.
163. Kuruvilla J., Shepherd J.D., Sutherland H.J., et al. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2007, 13:925-931.
164. Gahrton G., Tura S., Ljungman P., et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995, 13:1312-1322.
165. Martinelli G., Terragna C., Zamagni E., et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000, 18:2273-2281.
166. van de Donk N.W., Kroger N., Hegenbart U., et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006, 107:3415-3416.
167. Bruno B., Patriarca F., Sorasio R., et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006, 91:837-839.
168. El-Cheikh J., Michallet M., Nagler A., et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008, 93:455-458.
169. Minnema M.C., van der Veer M.S., Aarts T., Emmelot M., Mutis T., Lokhorst H.M. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009, 23:605-607.
170. Peggs K.S., Mackinnon S., Linch D.C. The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol 2005, 128:153-168.
171. Peggs K.S., Anderlini P., Sureda A. Allogeneic transplantation for Hodgkin lymphoma. Br J Haematol 2008, 143:468-480.
172. Kim S.W., Tanimoto T.E., Hirabayashi N., et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006, 108:382-389.
173. Freytes C.O., Loberiza F.R., Rizzo J.D., et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004, 104:3797-3803.
174. Baron F., Storb R., Storer B.E., et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006, 24:4150-4157.
175. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104:3865-3871.
176. Tomblyn M., Brunstein C., Burns L.J., et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:538-545.
177. Apostolidis J., Foran J.M., Johnson P.W., et al. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1999, 17:216-221.
178. Shamash J., Lee S.M., Radford J.A., et al. Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol 2000, 11:715-719.
179. Faulkner R.D., Craddock C., Byrne J.L., et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004, 103:428-434.
180. Russell N.H., Byrne J.L., Faulkner R.D., Gilyead M., Das-Gupta E.P., Haynes A.P. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:437-441.
181. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007, 21:2316-2323.
182. Armand P., Kim H.T., Ho V.T., et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008, 14:418-425.
183. van Besien K., Carreras J., Bierman P.J., et al. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009, 15:554-563.
184. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007, 110:2744-2748.
185. Peggs K.S., Sureda A., Qian W., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007, 139:70-80.
186. Robinson S.P., Sureda A., Canals C., et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009, 94:230-238.
187. Thomson K.J., Peggs K.S., Smith P., et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008, 41:765-770.
188. Claviez A., Canals C., Dierickx D., et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin's lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009, 114:2060-2067.
189. Burroughs L.M., O'Donnell P.V., Sandmaier B.M., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:1279-1287.
190. Devetten M.P., Hari P.N., Carreras J., et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009, 15:109-117.
191. van Besien K., Sobocinski K.A., Rowlings P.A., et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998, 92:1832-1836.
192. van Besien K., Champlin I.K., McCarthy P. Allogeneic transplantation for low-grade lymphoma: long-term follow-up. J Clin Oncol 2000, 18:702-703.
193. van Besien K., Loberiza F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102:3521-3529.
194. Kuruvilla J., Pond G., Tsang R., Gupta V., Lipton J.H., Messner H.A. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. Biol Blood Marrow Transplant 2008, 14:775-782.
195. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310-4316.
196. Vigouroux S., Michallet M., Porcher R., et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007, 92:627-634.
197. Rezvani A.R., Norasetthada L., Gooley T., et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008, 143:395-403.
198. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
199. Ratanatharathorn V., Logan B., Wang D., et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009, 145:816-824.
200. Ingram W., Devereux S., Das-Gupta E.P., et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008, 141:235-243.
201. Rezvani A.R., Storer B., Maris M., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:211-217.
202. Doocey R.T., Toze C.L., Connors J.M., et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005, 131:223-230.
203. Ramadan K.M., Connors J.M., Al-Tourah A.J., et al. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant 2008, 42:601-608.
204. Thomson K.J., Morris E.C., Bloor A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:426-432.
205. Hamadani M., Benson D.M., Hofmeister C.C., et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant 2009, 15:547-553.
206. Bishop M.R., Dean R.M., Steinberg S.M., et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008, 19:1935-1940.
207. Kyriakou C., Canals C., Finke J., et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009, 27:3951-3958.
208. de Lavallade H., Cassier P.A., Bouabdallah R., et al. Sustained response after reduced-intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T-cell non-Hodgkin lymphoma. Br J Haematol 2008, 142:848-850.
209. Woessmann W., Peters C., Lenhard M., et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents-a Berlin-Frankfurt-Munster group report. Br J Haematol 2006, 133:176-182.
210. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004, 104:3535-3542.
211. Ganti A.K., Bierman P.J., Lynch J.C., Bociek R.G., Vose J.M., Armitage J.O. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005, 16:618-624.
212. Kasamon Y.L., Jones R.J., Diehl L.F., et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2005, 11:39-46.
213. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
214. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003, 21:4407-4412.
215. Ben-Bassat I., Raanani P., Gale R.P. Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant 2007, 39:441-446.
216. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
217. Dreger P., Corradini P., Kimby E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12-17.
218. Sorror M.L., Storer B.E., Sandmaier B.M., et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008, 26:4912-4920.
219. Schetelig J., van Biezen A., Brand R., et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008, 26:5094-5100.
220. Delgado J., Pillai S., Benjamin R., et al. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2008, 14:1288-1297.
221. Brown J.R., Kim H.T., Li S., et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006, 12:1056-1064.
222. Delgado J., Milligan D.W., Dreger P. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?. Blood 2009, 114:2581-2588.
223. Khouri I.F., Keating M.J., Saliba R.M., Champlin R.E. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 2002, 4:217-221.
224. Khouri I.F., Saliba R.M., Admirand J., et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007, 137:355-363.
225. Dreger P., Ritgen M., Bottcher S., Schmitz N., Kneba M. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile?. Leukemia 2005, 19:1135-1138.
226. Ritgen M., Bottcher S., Stilgenbauer S., et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 2008, 22:1377-1386.
227. Klein J.P., Rizzo J.D., Zhang M.J., Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001, 28:909-915.
228. Klein J.P., Rizzo J.D., Zhang M.J., Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001, 28:1001-1011.
229. Klein JP, Zhang MJ. Survival Analysis. Handbook of Statistics, 2007:281-317.
230. Martinussen T., Scheike T.H. Dynamic Regression Models for Survival Data 2006, Springer, New York.
231. Pintilie M. Competing Risks: A Practical Perspective 2006, John Wiley & Sons, New York.
232. Klein J.P., Moeschberger M.L. Survival Analysis: Techniques for Censored and Truncated Data 2003, Springer, New York.
233. Zhang M.J., Zhang X., Scheike T.H. Modeling cumulative incidence function for competing risks data. Expert Rev Clin Pharmacol 2008, 1:391-400.
234. Gray R.J. A Class of K-sample tests for comparing the cumulative incidence of a copeting risk. Ann Stat 1988, 16:1141-1154.
235. Gray R.J. The cmprsk Package 2006.
236. Scrucca L., Santucci A., Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007, 40:381-387.
237. Zhang M.J., Fine J. Summarizing differences in cumulative incidence functions. Stat Med 2008, 27:4939-4949.
238. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997, 16:901-910.
239. Fine J.P., Gray Rj. A Proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
240. Klein J.P., Andersen P.K. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics 2005, 61:223-229.
241. Klein J.P., Gerster M., Andersen P.K., Tarima S., Perme M.P. SAS and R functions to compute pseudo-values for censored data regression. Comput Methods Programs Biomed 2008, 89:289-300.
242. Scheike T.H., Zhang M.J., Gerds T.A. Predicting cumulative incidence probability by direct binomial regression. Biometrika 2008, 95:205-220.
243. Scheike T.H., Zhang M.J. Flexible competing risks regression modeling and goodness-of-fit. Lifetime Data Anal 2008, 14:464-483.
244. Latouche A., Porcher R., Chevret S. A note on including time-dependent covariate in regression model for competing risks data. Biom J 2005, 47:807-814.